Gilead wins reversal of $2.54 billion hepatitis C drug patent verdict

(Reuters) – A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *